5α,6α-epoxycholestanol (5α,6α-EC) is a liver X receptor (LXR) antagonist. 5α,6α-EC is employed in anticancer treatments. It impairs redox state and affects atherogenesis. The levels of 5α,6α-EC are elevated in hypercholesterolemia. It mediates steroid receptor coactivator (SRC) recruitment.
